Episode 68
Biotech Hangout
00:00
The FDA's Concern About Short Course Treatments for Chronic Diseases
Our view was one, 35% chance that they get both indications. Two, 33% chance that it's just approved in PPD,. And three is a CRL for both indications. Daphne: So I think there are some questions around how should the FDA look at this treatment for such a short course or short duration on a disease that is generally perceived to be chronic.Yeah. The interesting thing that got everyone in the tussle over the last two weeks was that our good friend, Chris V. Bocker, had some very bullish comments about this earlier this year and called it perhaps one of the most exciting drivers for biogen for 2024.
Transcript
Play full episode
